Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
08.01. | Bioatla-Aktie fällt auf 52-Wochen-Tief von 0,57 US-Dollar | 6 | Investing.com Deutsch | ||
08.01. | Bioatla stock hits 52-week low at $0.57 amid sharp decline | 10 | Investing.com | ||
20.12.24 | BioAtla announces $9.2 million stock and warrant sale | 6 | Investing.com | ||
20.12.24 | BioAtla announces registered direct offering to advance two mid-stage clinical programs, shares fall | 9 | Seeking Alpha | ||
20.12.24 | BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points | 2 | GlobeNewswire (USA) | ||
20.12.24 | BioAtla, Inc. - 8-K, Current Report | - | SEC Filings | ||
BIOATLA Aktie jetzt für 0€ handeln | |||||
16.12.24 | BioAtla, Inc.: BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science ... | 3 | GlobeNewswire (USA) | ||
10.12.24 | BioAtla, Inc.: BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting | 6 | GlobeNewswire (USA) | ||
18.11.24 | BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 7.1% in October | 1 | MarketBeat | ||
14.11.24 | Michael Burry's Scion fund exits BioAtla, boosts Alibaba stake, adds puts: top Q3 trades | 26 | Seeking Alpha | ||
07.11.24 | BioAtla, Inc. - 10-Q, Quarterly Report | 9 | SEC Filings | ||
07.11.24 | BioAtla, Inc. - 8-K, Current Report | - | SEC Filings | ||
28.10.24 | BioAtla, Inc. (NASDAQ:BCAB) Sees Large Increase in Short Interest | 16 | MarketBeat | ||
20.10.24 | BioAtla, Inc. (BCAB): Among Michael Burry's Top 10 Stock Picks Heading Into 2025 | 6 | Insider Monkey | ||
04.10.24 | BioAtla, Inc.: BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting | 2 | GlobeNewswire (USA) | ||
01.10.24 | BioAtla, Inc.: BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress | 2 | GlobeNewswire (USA) | ||
23.09.24 | BioAtla out-licenses BA3362 to Context Therapeutics | 1 | Seeking Alpha | ||
23.09.24 | Context builds up bank of bispecific antibodies with up to $133M biobucks deal for BioAtla asset | 2 | FierceBiotech | ||
23.09.24 | BioAtla Grants Exclusive, Worldwide License To Context Therapeutics To Develop BA3362 | 6 | RTTNews | ||
23.09.24 | BioAtla licenses cancer drug candidate to Context Therapeutics | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,910 | -1,12 % | Chartanalyse: Evotec-Aktie: Es wird schon wieder kritisch! | © Foto: Christian Charisius/dpa - dpa-BildfunkIn der Aktie von Evotec ist es vor kurzem zu einem Kaufsignal gekommen. Das hat bislang aber keine Wirkung entfalten können. Der Chartcheck!Hinter den Evotec-Aktionären... ► Artikel lesen | |
BB BIOTECH | 39,900 | -0,62 % | BB Biotech - A positive start to a promising year | BB Biotech (BION) is the largest biotech investor among its investment company peers. The company is focused on achieving long-term capital growth by investing in high-quality biotech assets developing... ► Artikel lesen | |
CUREVAC | 3,768 | -1,77 % | CureVac Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
INFLARX | 2,304 | -4,48 % | InflaRx: Zulassung! | Die deutsche Biotech-Gesellschaft InflaRx kann einen wichtigen Meilenstein verbuchen. Denn die Europäische Kommission hat die Zulassung für Gohibic (Vilobelimab) zur Behandlung des SARS-CoV-2-induzierten... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 10,935 | +3,45 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema | CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
AFFIMED | 1,090 | +1,87 % | Affimed N.V.: Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated... ► Artikel lesen | |
ABCELLERA BIOLOGICS | 3,381 | -0,41 % | Abcellera Biologics, other AI health stocks gain as Ellison touts AI's promise | ||
COHERUS | 1,194 | -5,50 % | Coherus BioSciences, Inc.: Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 | - Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate - - Antitumor... ► Artikel lesen | |
OCULAR THERAPEUTIX | 7,706 | +0,36 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to redefining the retina experience, today... ► Artikel lesen | |
BEAM THERAPEUTICS | 26,295 | -0,28 % | Beam Therapeutics to present updated BEAM-101 trial data | ||
CHIMERIX | 3,615 | -0,28 % | Chimerix-Aktie erreicht 52-Wochen-Hoch bei 3,8 US-Dollar | ||
CYTOMX THERAPEUTICS | 0,848 | +5,54 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update | - Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated... ► Artikel lesen | |
SPERO THERAPEUTICS | 0,868 | +3,09 % | Spero Therapeutics, Inc.: Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes | Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company's Response to a Wells Notice... ► Artikel lesen | |
CIDARA THERAPEUTICS | 21,000 | 0,00 % | Cidara Therapeutics, Inc.: Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza | SAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies... ► Artikel lesen | |
NEXTCURE | 0,742 | -3,89 % | NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers | BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class... ► Artikel lesen |